A Bioinformatics Investigation of Hub Genes Involved in Treg Migration and Its Synergistic Effects, Using Immune Checkpoint Inhibitors for Immunotherapies
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25179341 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Nari Kim und 5 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Research Center, Asan Institute for Life Sciences, Asan Medical Center, Seoul 05505, Republic of Korea. Hauptthemen laut MEDLINE: Computational Biology, Immune Checkpoint Inhibitors, Immunotherapy, T-Lymphocytes, Regulatory. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, National Research Foundation, Korea Health Industry Development Institute.
Abstract (Originalsprache)
This study aimed to identify hub genes involved in regulatory T cell (Treg) function and migration, offering insights into potential therapeutic targets for cancer immunotherapy. We performed a comprehensive bioinformatics analysis using three gene expression microarray datasets from the GEO database. Differentially expressed genes (DEGs) were identified to pathway enrichment analysis to explore their functional roles and potential pathways. A protein-protein interaction network was constructed to identify hub genes critical for Treg activity. We further evaluated the co-expression of these hub genes with immune checkpoint proteins (PD-1, PD-L1, CTLA4) and assessed their prognostic significance. Through this comprehensive analysis, we identified CCR8 as a key player in Treg migration and explored its potential synergistic effects with ICIs. Our findings suggest that CCR8-targeted therapies could enhance cancer immunotherapy outcomes, with breast invasive carcinoma (BRCA) emerging as a promising indication for combination therapy. This study highlights the potential of CCR8 as a biomarker and therapeutic target, contributing to the development of targeted cancer treatment strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biomedical Research Center, Asan Institute for Life Sciences, Asan Medical Center, Seoul 05505, Republic of Korea.
- College of Pharmacy, Chungbuk National University, Cheongju 28644, Republic of Korea.
- Trial Informatics Inc., Seoul 05544, Republic of Korea.
- Samjin Pharmaceutical Co., Ltd., Seoul 04054, Republic of Korea.
- Departments of Radiology and Research Institute of Radiology, Asan Medical Center, College of Medicine, University of Ulsan, Olymphic-ro 43 Gil 88, Songpa-gu, Seoul 05505, Republic of Korea.
ORCID-Profile: Nari Kim, Jisung Jang, Kyungwon Kim
Förderung
- National Research Foundation of Korea
- National Research Foundation
- Korea Health Industry Development Institute
- Korean government (MSIT)
- Ministry of Health & Welfare, Republic of Korea
Zitieren
APA
Kim, N., Na, S., Pyo, J., Jang, J., Lee, S. M., & Kim, K. (2024). A Bioinformatics Investigation of Hub Genes Involved in Treg Migration and Its Synergistic Effects, Using Immune Checkpoint Inhibitors for Immunotherapies. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25179341
Vancouver
Kim N, Na S, Pyo J, Jang J, Lee SM, Kim K. A Bioinformatics Investigation of Hub Genes Involved in Treg Migration and Its Synergistic Effects, Using Immune Checkpoint Inhibitors for Immunotherapies. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25179341
BibTeX
@article{Kim2024,
author = {Kim, Nari and Na, Seoungwon and Pyo, Junhee and Jang, Jisung and Lee, Soo-Min and Kim, Kyungwon},
title = {A Bioinformatics Investigation of Hub Genes Involved in Treg Migration and Its Synergistic Effects, Using Immune Checkpoint Inhibitors for Immunotherapies},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25179341}
}
EUVIMED